Research study Program year 2024 Source: CMS Open Payments

PK Bridging (PFS vs Autoinjector)

Research payments

$169,840

3 payments

Through program year 2024, $169,840 in research payments was reported against PK Bridging (PFS vs Autoinjector), across 3 payments, paid by Celgene Corporation.

Paid by
Celgene Corporation
ClinicalTrials.gov
No trial number was reported for this study

By program year

3 rows
Year Kind Amount Payments
2024 Research $330 1
2023 Research $69,700 1
2022 Research $99,810 1

Breakdown

Who paid Research payments · program years 2022–2024
  1. Celgene Corporation $169,840 3 payments
Who received the money Research payments · program years 2022–2024
  1. Qps Organisation paid for research $169,840 3 payments

Usually the institution or organisation running the study, not a person.

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

1 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record